Examination of the evidence for off-label use of gabapentin.

@article{Mack2003ExaminationOT,
  title={Examination of the evidence for off-label use of gabapentin.},
  author={Alicia Mack},
  journal={Journal of managed care pharmacy : JMCP},
  year={2003},
  volume={9 6},
  pages={
          559-68
        }
}
  • A. Mack
  • Published 2003
  • Medicine
  • Journal of managed care pharmacy : JMCP
OBJECTIVES (1) Describe the relevance of off-label use of gabapentin to managed care pharmacy; (2) summarize recent FDA warnings and media reports related to off-label gabapentin use; (3) review medical information pertaining to the off-label use of gabapentin; (4) outline alternatives to off-label use of gabapentin in an evidence-based fashion, where literature exists to support such alternatives; and (5) encourage key clinicians and decision makers in managed care pharmacy to develop and… Expand
Gabapentin for Off-Label Use: Evidence-Based or Cause for Concern?
TLDR
Clinicians should exercise rigorous appraisal of the available evidence for a given indication, and researchers should conduct larger, higher-quality studies to better assess the efficacy of gabapentin for many of its off-label uses. Expand
"Off-label" Prescribing of Gabapentin: An Exploratory Study
TLDR
Lack of provincial-government reimbursement for offlabel uses of gabapentin (knowledge of drug coverage) was a significant barrier to prescribing and knowledge from various interconnected sources influenced off-label prescribing decisions. Expand
The Rise and Fall of Gabapentin for Bipolar Disorder: A Case Study on Off-Label Pharmaceutical Diffusion
TLDR
Evidence of inefficacy and/or the cessation of pharmaceutical marketing, and a restrictive formulary policy can alter prescriber behavior away from targeted pharmacologic treatments, suggest that both information and policy are important means in altering physician prescribing behavior. Expand
Impact of a clinical pharmacy consult service on guideline adherence and management of gabapentin for neuropathic pain.
TLDR
A clinical pharmacy intervention as part of the management of a treatment guideline for appropriate gabapentin use promotes documentation of drug therapy effectiveness in neuropathic pain and prevention of gabAPentin use prior to a trial with alternative first-line therapies. Expand
Prevalence of Gabapentin Abuse: Comparison with Agents with Known Abuse Potential in a Commercially Insured US Population
TLDR
Gabapentin use patterns are similar to those of other abusable medications, and high daily doses pose safety and/or diversion concerns, and investigation of the medical consequences of gabapentin abuse is needed. Expand
Gabapentinoids: pharmacokinetics, pharmacodynamics and considerations for clinical practice
The gabapentinoids are often recommended as first-line treatments for the management of neuropathic pain. The differing pharmacodynamic and pharmacokinetic profiles can have implications for clinicalExpand
Characterization of gabapentin use in Kentucky after reclassification as a Schedule V controlled substance.
TLDR
Gabapentin is widely prescribed in Kentucky, with higher rates of use observed in females, those older than 55 years and individuals living in the Appalachian region, and future studies are needed to assess the risks associated with gabapentin use. Expand
Prescribing Gabapentin off Label: Perspectives from Psychiatry, Pain and Neurology Specialists
TLDR
There is a need for greater understanding of off-label prescribing practices as an important step toward improving rational prescribing and ultimately toward improving patient safety and health outcomes. Expand
Gabapentin and pregabalin: do the benefits outweigh the harms?
TLDR
Prescribers should be aware of the very limited clinical evidence for use of gabapentin and pregabalin outside their licensed indications, as well as their capacity to do harm. Expand
Gabapentin use, abuse, and the US opioid epidemic: the case for reclassification as a controlled substance and the need for pharmacovigilance
TLDR
State-by-state efforts to enhance pharmacovigilance are reported and a re-evaluation of the schedule status of gabapentin at the federal level, and design and implementation of a national pharmacov Vigilance program are called for. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 90 REFERENCES
Gabapentin use in a managed medicaid population.
TLDR
Almost all patients in this sample from the Medicaid managed population received gabapentin for off-label indications, and evidence from clinical trials does not support the use of gabAPentin for many of the conditions treated with gABapentin in this study. Expand
Gabapentin: A New Agent for the Management of Epilepsy
TLDR
Gabapentin appears to be a useful new AED, and further studies evaluating its use as monotherapy, in higher dosages, and in pediatric and elderly patients are required to better delineate its therapeutic role relative to that of other AEDs. Expand
Gabapentin for the Treatment of Postherpetic Neuralgia
TLDR
Gabapentin may be a useful adjunct for treating intractable postherpetic neuralgia with a minimal side effects. Expand
An open label study of gabapentin in the treatment of acute mania.
TLDR
It is suggested that gabapentin monotherapy might be useful in selected patients to treat modest but not severe manic states and in conjunction with other effective mood stabilisers seems to be safe and efficacious in the treatment of severe mania. Expand
Newer Antiepileptic Drugs in Bipolar Disorder
TLDR
Current evidence suggests efficacy of lamotrigine both as monotherapy and as an adjunctive agent in bipolar depression, and studies are underway to clarify its efficacy in mood stabilisation and rapid cycling, as currently available data are equivocal. Expand
Gabapentin: A Review of Published Experience in the Treatment of Bipolar Disorder and Other Psychiatric Conditions
TLDR
Gabapentin is a relatively new anticonvulsant being investigated for potential use in the treatment of bipolar disorder (BD), anxiety disorders, behavioral dyscontrol, and substance use disorders and its favorable side effect profile, absence of the need for therapeutic drug monitoring, and minimal drug interactions give gabapentin a potential role in these indications. Expand
Gabapentin and methylphenidate treatment of a preadolescent with attention deficit hyperactivity disorder and bipolar disorder.
  • V. Hamrin, K. Bailey
  • Psychology, Medicine
  • Journal of child and adolescent psychopharmacology
  • 2001
TLDR
A 12-year-old boy with a history of attention deficient hyperactivity disorder, reading disorder, mixed receptive and expressive language disorder, encopresis, and bipolar disorder II who was treated with gabapentin 200mg/day added to methylphenidate 30 mg/day within 3 weeks the improvement and stabilization of mood symptoms was remarkable, as noted by mother, teacher, and clinician. Expand
Gabapentin in the treatment of adolescent mania: a case report.
TLDR
A 13-year-old boy with bipolar I disorder, manic episode, and ADHD, was treated with gabapentin 1,500 mg/day as add-on therapy to carbamazepine and showed a marked response within 1 month. Expand
Reflex sympathetic dystrophy treated with gabapentin.
TLDR
The use of the recently released anticonvulsant, gabapentin (Neurontin), in the treatment of severe and refractory reflex sympathetic dystrophy (RSD) pain in six patients ranging in age from 42 to 68 years suggests that this medication is an effective treatment for RSD pain. Expand
Gabapentin: A unique anti-epileptic agent
TLDR
Overall, gabapentin has a low incidence of adverse effects, a pharmacokinetic profile that limits its drug interactions, and limited effects on cognition when compared to traditional AEDs. Expand
...
1
2
3
4
5
...